Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix?

Edward P.K. Parker; Shalini Desai; Melanie Marti; Katherine L. O'Brien; David C. Kaslow; Sonali Kochhar; Folake Olayinka; Alejandro Cravioto; Hanna Nohynek; Joachim Hombach; Annelies Wilder-Smith

doi:10.1016/S1473-3099(22)00178-5

Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix?

Edward P.K. Parker, Shalini Desai, Melanie Marti, Katherine L. O'Brien, David C. Kaslow, Sonali Kochhar, Folake Olayinka, Alejandro Cravioto, Hanna Nohynek, Joachim Hombach, Annelies Wilder-Smith

Bloomberg School of Public Health

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	438-440
Number of pages	3
Journal	The Lancet Infectious Diseases
Volume	22
Issue number	4
DOIs	https://doi.org/10.1016/S1473-3099(22)00178-5
State	Published - Apr 2022

ASJC Scopus subject areas

Infectious Diseases

Access to Document

10.1016/S1473-3099(22)00178-5

Cite this

@article{de6fd5101ea648f391f540d8c4d3e915,

title = "Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix?",

author = "Parker, {Edward P.K.} and Shalini Desai and Melanie Marti and O'Brien, {Katherine L.} and Kaslow, {David C.} and Sonali Kochhar and Folake Olayinka and Alejandro Cravioto and Hanna Nohynek and Joachim Hombach and Annelies Wilder-Smith",

year = "2022",

month = apr,

doi = "10.1016/S1473-3099(22)00178-5",

language = "English (US)",

volume = "22",

pages = "438--440",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",